Egon Pfarr

2.9k total citations · 2 hit papers
25 papers, 1.8k citations indexed

About

Egon Pfarr is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Egon Pfarr has authored 25 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in Egon Pfarr's work include Diabetes Treatment and Management (22 papers), Pancreatic function and diabetes (14 papers) and Diabetes Management and Research (7 papers). Egon Pfarr is often cited by papers focused on Diabetes Treatment and Management (22 papers), Pancreatic function and diabetes (14 papers) and Diabetes Management and Research (7 papers). Egon Pfarr collaborates with scholars based in Germany, United States and United Kingdom. Egon Pfarr's co-authors include Stuart Pocock, João Pedro Ferreira, Gerasimos Filippatos, Milton Packer, Faı̈ez Zannad, Javed Butler, Stefan D. Anker, Martina Brueckmann, Anne Pernille Ofstad and Waheed Jamal and has published in prestigious journals such as The Lancet, Circulation and Kidney International.

In The Last Decade

Egon Pfarr

24 papers receiving 1.8k citations

Hit Papers

SGLT2 inhibitors in patients with heart failure with redu... 2019 2026 2021 2023 2020 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
    2020 831 citations Faı̈ez Zannad, João Pedro Ferreira et al. The Lancet profile →
  2. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
    2019 243 citations David Fitchett, Silvio E. Inzucchi et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Egon Pfarr Germany 15 1.4k 750 571 488 361 25 1.8k
Anne Pernille Ofstad Germany 21 1.4k 1.0× 951 1.3× 602 1.1× 518 1.1× 371 1.0× 59 2.0k
Waheed Jamal United States 15 1.6k 1.1× 1.4k 1.9× 632 1.1× 523 1.1× 497 1.4× 21 2.4k
Cordula Zeller Germany 19 2.0k 1.5× 982 1.3× 887 1.6× 837 1.7× 426 1.2× 42 2.6k
George L. Bakris United States 5 1.3k 0.9× 606 0.8× 301 0.5× 325 0.7× 369 1.0× 11 1.8k
Silvina Gallo United States 10 1.3k 1.0× 277 0.4× 521 0.9× 596 1.2× 253 0.7× 14 1.5k
Egon Pfarr Germany 12 1.5k 1.1× 421 0.6× 489 0.9× 497 1.0× 115 0.3× 20 1.8k
K. J. Schjoedt Denmark 13 909 0.7× 758 1.0× 179 0.3× 218 0.4× 235 0.7× 16 1.3k
Arihiro Kiyosue Japan 19 507 0.4× 274 0.4× 486 0.9× 377 0.8× 164 0.5× 72 1.2k
Robin Mukherjee United States 11 879 0.6× 1.2k 1.6× 1.0k 1.8× 172 0.4× 314 0.9× 16 2.1k
Bruce R. Leslie United States 8 956 0.7× 209 0.3× 471 0.8× 389 0.8× 167 0.5× 16 1.2k

Countries citing papers authored by Egon Pfarr

Since Specialization
Citations

This map shows the geographic impact of Egon Pfarr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Egon Pfarr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Egon Pfarr more than expected).

Fields of papers citing papers by Egon Pfarr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Egon Pfarr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Egon Pfarr. The network helps show where Egon Pfarr may publish in the future.

Co-authorship network of co-authors of Egon Pfarr

This figure shows the co-authorship network connecting the top 25 collaborators of Egon Pfarr. A scholar is included among the top collaborators of Egon Pfarr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Egon Pfarr. Egon Pfarr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sattar, Naveed, Javed Butler, Matthew M.Y. Lee, et al.. (2024). Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial. European Journal of Heart Failure. 26(4). 900–909. 15 indexed citations
2.
Wanner, Christoph, et al.. (2024). Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in Therapy. 41(7). 2826–2844. 7 indexed citations
3.
Sharma, Abhinav, João Pedro Ferreira, Faı̈ez Zannad, et al.. (2023). Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial. European Journal of Heart Failure. 25(8). 1337–1348. 33 indexed citations
4.
Anker, Stefan D., Muhammad Shahzeb Khan, Javed Butler, et al.. (2022). Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced. European Journal of Heart Failure. 25(1). 117–127. 36 indexed citations
5.
Feldman, M., Christoph Wanner, Egon Pfarr, et al.. (2021). Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. American Journal of Kidney Diseases. 79(6). 796–806. 32 indexed citations
6.
Zannad, Faı̈ez, João Pedro Ferreira, Stuart Pocock, et al.. (2020). Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation. 143(4). 310–321. 180 indexed citations
7.
Zannad, Faı̈ez, João Pedro Ferreira, Stuart Pocock, et al.. (2020). SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 396(10254). 819–829. 831 indexed citations breakdown →
8.
Sone, Hirohito, et al.. (2019). Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial. Diabetes Obesity and Metabolism. 22(3). 417–426. 22 indexed citations
9.
10.
Fitchett, David, Silvio E. Inzucchi, Christopher P. Cannon, et al.. (2019). Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 139(11). 1384–1395. 243 indexed citations breakdown →
11.
Perkovic, Vlado, Audrey Koitka‐Weber, Mark E. Cooper, et al.. (2019). Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. Nephrology Dialysis Transplantation. 35(12). 2103–2111. 20 indexed citations
12.
13.
14.
Pfarr, Egon, et al.. (2017). Effect of Empagliflozin on Albuminuria in Patients with Type 2 Diabetes and High Cardiovascular Risk. 59(3). 376. 1 indexed citations
15.
Cherney, David Z.I., Mark E. Cooper, Ilkka Tikkanen, et al.. (2017). Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney International. 93(1). 231–244. 181 indexed citations
16.
17.
Romera, Irene, et al.. (2016). Eficacia y seguridad de empagliflozina en combinación con otros hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2. Endocrinología y Nutrición. 63(10). 519–526. 10 indexed citations
18.
Chirila, Costel, et al.. (2015). Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research. 25(5). 1199–1207. 6 indexed citations
19.
Beuscher, N., et al.. (2005). Tolerability and efficacy of Bioaron CReg. syrup in treatment of upper respiratory tract infections in children. Results of a post-marketing surveillance study in Poland. Herba Polonica. 51. 45–53. 1 indexed citations
20.
Lüders, Stephan, F. Hammersen, Anke Kulschewski, et al.. (2005). Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice. International Journal of Clinical Practice. 59(6). 632–638. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne Pernille Ofstad Breakdown of academic impact, for papers by Waheed Jamal Breakdown of academic impact, for papers by Cordula Zeller Breakdown of academic impact, for papers by George L. Bakris Breakdown of academic impact, for papers by Silvina Gallo Breakdown of academic impact, for papers by Egon Pfarr Breakdown of academic impact, for papers by K. J. Schjoedt Breakdown of academic impact, for papers by Arihiro Kiyosue Breakdown of academic impact, for papers by Robin Mukherjee Breakdown of academic impact, for papers by Bruce R. Leslie
Rankless by CCL
2026